--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-26-257432" form_type: "8-K" ticker: "RPRX" cik: "0001802768" company_name: "Royalty Pharma plc" filed_at: "2026-06-04T20:15:59+00:00" generated_at: "2026-06-04T20:51:20.491653+00:00" event_type: "other" sentiment: "neutral" materiality_score: 0.2 calibrated_materiality_score: 0.15 confidence: "high" source: SEC EDGAR --- # Royalty Pharma announces 2026 AGM results; all director nominees elected ## Summary - All 9 director nominees elected with 88.08% quorum; Pablo Legorreta received 458.2M votes for, 29.4M against. - Say-on-pay (non-binding) approved: 476.0M for, 11.1M against, 0.7M abstain. - Ratification of Ernst & Young as independent auditor: 506.3M for, 0.8M against, 1.0M abstain. - UK statutory accounts and reports approved: 487.2M for, 98K against, 0.6M abstain. - Authorization to allot shares without pre-emption passed: 445.7M for, 42.0M against. ## SEC filing metadata - accession: 0001193125-26-257432 - form_type: 8-K - ticker: RPRX - cik: 0001802768 - company_name: Royalty Pharma plc - filed_at: 2026-06-04T20:15:59+00:00 - event_type: other - sentiment: neutral - materiality_score: 0.2 - calibrated_materiality_score: 0.15 - confidence: high - sec_items: 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312526257432/0001193125-26-257432-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312526257432/d855771d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-26-257432 - JSON: https://secwatch.observer/filing/0001193125-26-257432.json - Plain text: https://secwatch.observer/filing/0001193125-26-257432.txt ## Key facts - Shareholder Votes Royalty Pharma plc shareholders approved Approval of U.K. statutory accounts and reports at the 2026-06-04 meeting. - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 4. To approve receipt of the Company’s U.K. statutory accounts together with the Company’s U.K. statutory reports, including the directors’ report, the strategic report, the directors’ remuneration report and the auditors’ report for the fiscal year ended December 31, 2025 ("U.K. Annual Report and Accounts") : evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312526257432/0001193125-26-257432-index.htm - Shareholder Votes Royalty Pharma plc shareholders approved Authorization for Board to determine U.K. statutory auditor remuneration at the 2026-06-04 meeting. - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 7. To authorize the Board of Directors to determine the remuneration of the Company’s U.K. statutory auditor: evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312526257432/0001193125-26-257432-index.htm - Shareholder Votes Royalty Pharma plc shareholders approved Approval of share purchase agreements and counterparties at the 2026-06-04 meeting. - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 8. To approve the terms of the agreements and counterparties pursuant to which the Company may purchase its Class A ordinary shares: evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312526257432/0001193125-26-257432-index.htm - Shareholder Votes Royalty Pharma plc shareholders approved Ratification of Ernst & Young LLP as independent auditor at the 2026-06-04 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 3. To ratify the appointment of Ernst & Young LLP, as the Company’s independent registered public accounting firm: evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312526257432/0001193125-26-257432-index.htm - Shareholder Votes Royalty Pharma plc shareholders approved Advisory vote on executive compensation at the 2026-06-04 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 2. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers: evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312526257432/0001193125-26-257432-index.htm - Shareholder Votes Royalty Pharma plc shareholders approved Election of nine directors at the 2026-06-04 meeting. - Proposal: director election - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 1. To elect nine directors, each by separate ordinary resolutions, to the Company’s Board of Directors to serve until the 2027 Annual General Meeting of Shareholders: evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312526257432/0001193125-26-257432-index.htm - Shareholder Votes Royalty Pharma plc shareholders approved Re-appointment of Ernst & Young as U.K. statutory auditor at the 2026-06-04 meeting. - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 6. To re-appoint Ernst & Young as the Company’s U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are presented to shareholders: evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312526257432/0001193125-26-257432-index.htm - Shareholder Votes Royalty Pharma plc shareholders approved Advisory vote on U.K. directors' remuneration report at the 2026-06-04 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 5. To approve, on a non-binding advisory basis, the Company’s U.K. directors’ remuneration report in the U.K. Annual Report and Accounts: evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312526257432/0001193125-26-257432-index.htm - Shareholder Votes Royalty Pharma plc shareholders approved Authorization to allot shares at the 2026-06-04 meeting. - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 9. To authorize the Board of Directors to allot shares: evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312526257432/0001193125-26-257432-index.htm - Shareholder Votes Royalty Pharma plc shareholders approved Authorization to allot shares without pre-emptive rights at the 2026-06-04 meeting. - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 10. To authorize the Board of Directors to allot shares without rights of pre-emption: evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312526257432/0001193125-26-257432-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.